{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:40:33Z","timestamp":1790959233006,"version":"4.1.0"},"reference-count":209,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Vascular and Interventional Radiology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.jvir.2013.04.023","type":"journal-article","created":{"date-parts":[[2013,6,28]],"date-time":"2013-06-28T04:30:50Z","timestamp":1372393850000},"page":"1167-1188","source":"Crossref","is-referenced-by-count":29,"title":["Cancer Concepts and Principles: Primer for the Interventional Oncologist\u2014Part II"],"prefix":"10.1016","volume":"24","author":[{"given":"Ryan","family":"Hickey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Vouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Y.","family":"Sze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Hohlastos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Schirmang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khairuddin","family":"Memon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kent","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramona","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Resnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard B.","family":"Chrisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Albert A.","family":"Nemcek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Vogelzang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Lewandowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riad","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvir.2013.04.023_bib1","unstructured":"American Joint Committee on Cancer. Available at: http:\/\/www.cancerstaging.org\/staging\/index.html. Accessed November 2012."},{"key":"10.1016\/j.jvir.2013.04.023_bib2","unstructured":"National Cancer Institute. Fact sheet: tumor markers. Available at http:\/\/www.cancer.gov\/cancertopics\/factsheet\/detection\/tumor-markers. Accessed November 2012"},{"key":"10.1016\/j.jvir.2013.04.023_bib3","unstructured":"National Cancer Institute. Physician Data Query (PDQ). Available at: http:\/\/www.cancer.gov\/cancertopics\/pdq. Accessed November 2012."},{"key":"10.1016\/j.jvir.2013.04.023_bib4","unstructured":"National Comprehensive Cancer Network. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site. Accessed November 2012."},{"key":"10.1016\/j.jvir.2013.04.023_bib5","unstructured":"National Cancer Institute. Cancer Therapy Evaluation Program (CTEP). Available at: http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html. Accessed November 2012"},{"key":"10.1016\/j.jvir.2013.04.023_bib6","series-title":"DeVita, Hellman, and Rosenberg\u2019s cancer: principles and practice of oncology","author":"DeVita","year":"2011"},{"key":"10.1016\/j.jvir.2013.04.023_bib7","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1158\/1078-0432.CCR-07-2141","article-title":"Is cell death a critical end point for anticancer therapies or is cytostasis sufficient?","volume":"13","author":"Rixe","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jvir.2013.04.023_bib8","unstructured":"National Cancer Institute. NCI Dictionary of Cancer Terms. Available at: http:\/\/www.cancer.gov\/dictionary."},{"key":"10.1016\/j.jvir.2013.04.023_bib9","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1200\/JCO.1998.16.7.2468","article-title":"Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications","volume":"16","author":"Kwiatkowski","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib10","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2013.04.023_bib11","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMra0801289","article-title":"Gene-expression signatures in breast cancer","volume":"360","author":"Sotiriou","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2013.04.023_bib12","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1053\/j.gastro.2010.02.005","article-title":"Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer","volume":"138","author":"Winder","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jvir.2013.04.023_bib13","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1200\/JCO.2006.06.7595","article-title":"Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines","volume":"24","author":"Lenz","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib14","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2013.04.023_bib16","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.ejca.2012.02.057","article-title":"Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials","volume":"48","author":"Bokemeyer","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jvir.2013.04.023_bib17","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","article-title":"EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer","volume":"26","author":"Sobrero","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib18","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1158\/0008-5472.CAN-06-0191","article-title":"KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer","volume":"66","author":"Lievre","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.jvir.2013.04.023_bib19","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2013.04.023_bib20","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.critrevonc.2009.06.005","article-title":"Integration of panitumumab into the treatment of colorectal cancer","volume":"74","author":"Gravalos","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jvir.2013.04.023_bib21","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib22","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib23","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib24","first-page":"CD005392","article-title":"Anti-angiogenic therapies for metastatic colorectal cancer","author":"Wagner","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jvir.2013.04.023_bib25","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1046\/j.1523-1747.2002.01853.x","article-title":"Expression of transglutaminase 5 in normal and pathologic human epidermis","volume":"119","author":"Candi","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jvir.2013.04.023_bib26","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/362841a0","article-title":"Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo","volume":"362","author":"Kim","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.jvir.2013.04.023_bib27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","article-title":"Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer","volume":"21","author":"Kabbinavar","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib28","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2013.04.023_bib29","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1200\/JCO.2007.15.4138","article-title":"Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study","volume":"26","author":"Hochster","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib30","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib31","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2013.04.023_bib32","doi-asserted-by":"crossref","first-page":"6023","DOI":"10.1158\/1078-0432.CCR-11-3252","article-title":"Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer","volume":"18","author":"Tang","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jvir.2013.04.023_bib33","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib34","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2013.04.023_bib35","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2013.04.023_bib36","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib37","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2013.04.023_bib38","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/cncr.10195","article-title":"Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma","volume":"94","author":"Shojamanesh","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.jvir.2013.04.023_bib39","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2013.04.023_bib40","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2013.04.023_bib41","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib42","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jvir.2013.04.023_bib43","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jvir.2013.04.023_bib44","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/ssu.2980100105","article-title":"Residual tumor (R) classification and prognosis","volume":"10","author":"Hermanek","year":"1994","journal-title":"Semin Surg Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib45","first-page":"e001736","article-title":"Pulmonary metastasectomy for sarcoma: a systematic review of reported outcomes in the context of Thames Cancer Registry data","volume":"2","author":"Treasure","year":"2012","journal-title":"Br Med J"},{"key":"10.1016\/j.jvir.2013.04.023_bib46","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.hlc.2012.11.001","article-title":"Pulmonary metastasectomy for sarcoma of gynaecologic origin","volume":"22","author":"Paramanathan","year":"2013","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.jvir.2013.04.023_bib47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases","volume":"230","author":"Fong","year":"1999","journal-title":"Ann Surg"},{"key":"10.1016\/j.jvir.2013.04.023_bib48","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/01.sla.0000160703.75808.7d","article-title":"Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases","volume":"241","author":"Pawlik","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.jvir.2013.04.023_bib49","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11864-001-0053-1","article-title":"Advanced ovarian cancer","volume":"2","author":"van der Burg","year":"2001","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ygyno.2010.04.005","article-title":"Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis","volume":"118","author":"Barlin","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib51","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00534-005-0999-7","article-title":"Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system","volume":"12","author":"Strasberg","year":"2005","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"10.1016\/j.jvir.2013.04.023_bib52","first-page":"1951","article-title":"Impact of intraoperative radiotherapy (IORT) on survival of patients with unresectable hilar cholangiocarcinoma","volume":"55","author":"Kaiser","year":"2008","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.jvir.2013.04.023_bib53","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/BF01534842","article-title":"Cell cycle-dependent repair of double-strand DNA breaks in a gamma-ray-sensitive Chinese hamster cell","volume":"11","author":"Giaccia","year":"1985","journal-title":"Somat Cell Mol Genet"},{"key":"10.1016\/j.jvir.2013.04.023_bib54","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/jcb.20149","article-title":"Radiation-induced genomic instability: a role for secreted soluble factors in communicating the radiation response to non-irradiated cells","volume":"92","author":"Sowa Resat","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.jvir.2013.04.023_bib55","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrc1367","article-title":"Exploiting tumour hypoxia in cancer treatment","volume":"4","author":"Brown","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jvir.2013.04.023_bib56","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3109\/02841868509134389","article-title":"Radiation dose dependence of the sensitization by oxygen and oxygen mimic sensitizers","volume":"24","author":"Revesz","year":"1985","journal-title":"Acta Radiol Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib57","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1118\/1.3521406","article-title":"Tumor control probability in radiation treatment","volume":"38","author":"Zaider","year":"2011","journal-title":"Med Phys"},{"key":"10.1016\/j.jvir.2013.04.023_bib58","series-title":"Perez and Brady\u2019s principles and practice of radiation oncology","author":"Halperin","year":"2008"},{"key":"10.1016\/j.jvir.2013.04.023_bib59","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000262470","article-title":"Altered fractionation schemes in radiotherapy","volume":"42","author":"Stuschke","year":"2010","journal-title":"Front Radiat Ther Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib60","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/0360-3016(82)90459-X","article-title":"Dose fractionation, dose rate and iso-effect relationships for normal tissue responses","volume":"8","author":"Barendsen","year":"1982","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jvir.2013.04.023_bib61","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0167-8140(95)01525-L","article-title":"Does the interval between fractions matter in the range of 4-8h in radiotherapy? A study of acute and late human skin reactions","volume":"34","author":"Nyman","year":"1995","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib62","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0360-3016(82)90517-X","article-title":"Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships","volume":"8","author":"Thames","year":"1982","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jvir.2013.04.023_bib63","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/095530096145003","article-title":"Fluorodeoxyuridine-mediated cytotoxicity and radiosensitization require S phase progression","volume":"70","author":"Lawrence","year":"1996","journal-title":"Int J Radiat Biol"},{"key":"10.1016\/j.jvir.2013.04.023_bib64","first-page":"2246","article-title":"Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma","volume":"7","author":"Wolff","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jvir.2013.04.023_bib65","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semradonc.2005.08.001","article-title":"Biologic basis for combining drugs with radiation","volume":"16","author":"Wilson","year":"2006","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib66","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1634\/theoncologist.12-6-738","article-title":"Amifostine: the first selective-target and broad-spectrum radioprotector","volume":"12","author":"Kouvaris","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.jvir.2013.04.023_bib67","doi-asserted-by":"crossref","first-page":"e7765","DOI":"10.1136\/bmj.e7765","article-title":"Advances in radiotherapy","volume":"345","author":"Ahmad","year":"2012","journal-title":"Br Med J"},{"key":"10.1016\/j.jvir.2013.04.023_bib68","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.clon.2010.06.013","article-title":"A review of the clinical evidence for intensity-modulated radiotherapy","volume":"22","author":"Staffurth","year":"2010","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.jvir.2013.04.023_bib69","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0360-3016(01)01749-7","article-title":"Intensity-modulated radiotherapy: current status and issues of interest","volume":"51","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jvir.2013.04.023_bib70","doi-asserted-by":"crossref","first-page":"c3247","DOI":"10.1136\/bmj.c3247","article-title":"Radiosurgery for brain tumours","volume":"340","author":"Short","year":"2010","journal-title":"Br Med J"},{"key":"10.1016\/j.jvir.2013.04.023_bib71","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.rcl.2012.06.004","article-title":"Image-guided ablative therapies for lung cancer","volume":"50","author":"Sharma","year":"2012","journal-title":"Radiol Clin North Am"},{"key":"10.1016\/j.jvir.2013.04.023_bib72","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.clon.2009.12.003","article-title":"Stereotactic body radiotherapy: a review","volume":"22","author":"Martin","year":"2010","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.jvir.2013.04.023_bib73","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1200\/JCO.2006.09.7816","article-title":"Particle radiation therapy using proton and heavier ion beams","volume":"25","author":"Schulz-Ertner","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib74","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.radonc.2012.02.001","article-title":"An evidence based review of proton beam therapy: the report of ASTRO\u2019s emerging technology committee","volume":"103","author":"Allen","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib75","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/S0360-3016(99)00331-4","article-title":"Derivation of isoeffect dose rate for low-dose-rate brachytherapy and external beam irradiation","volume":"45","author":"Giap","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jvir.2013.04.023_bib76","doi-asserted-by":"crossref","DOI":"10.1245\/s10434-013-2923-8","article-title":"The evolving role of partial breast irradiation in early-stage breast cancer","author":"Barry","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"suppl 1","key":"10.1016\/j.jvir.2013.04.023_bib77","first-page":"28","article-title":"Options and recent advances in permanent brachytherapy for prostate cancer","volume":"14","author":"Marshall","year":"2007","journal-title":"Can J Urol"},{"key":"10.1016\/j.jvir.2013.04.023_bib78","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S1499-3872(11)60119-7","article-title":"Current therapy of hilar cholangiocarcinoma","volume":"11","author":"Lau","year":"2012","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"suppl 3","key":"10.1016\/j.jvir.2013.04.023_bib79","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S0960-9776(11)70307-1","article-title":"Intraoperative radiation therapy: is it a standard now?","volume":"20","author":"Orecchia","year":"2011","journal-title":"Breast"},{"key":"10.1016\/j.jvir.2013.04.023_bib80","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.suronc.2011.12.008","article-title":"Management of recurrent cervical cancer: a review of the literature","volume":"21","author":"Peiretti","year":"2012","journal-title":"Surg Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib81","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1148\/radiol.10090337","article-title":"Advanced hepatic ablation technique for creating complete cell death: irreversible electroporation","volume":"255","author":"Lee","year":"2010","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2013.04.023_bib82","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/153303460700600403","article-title":"Mathematical modeling of irreversible electroporation for treatment planning","volume":"6","author":"Edd","year":"2007","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.jvir.2013.04.023_bib83","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jamcollsurg.2012.04.029","article-title":"Ablation of perivascular hepatic malignant tumors with irreversible electroporation","volume":"215","author":"Kingham","year":"2012","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jvir.2013.04.023_bib84","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1148\/radiol.11110144","article-title":"Local-regional treatment of hepatocellular carcinoma","volume":"262","author":"Lencioni","year":"2012","journal-title":"Radiology"},{"issue":"suppl","key":"10.1016\/j.jvir.2013.04.023_bib85","doi-asserted-by":"crossref","first-page":"S179","DOI":"10.1016\/j.jvir.2010.04.008","article-title":"Radiofrequency ablation: mechanism of action and devices","volume":"21","author":"Hong","year":"2010","journal-title":"J Vasc Interv Radiol"},{"issue":"suppl","key":"10.1016\/j.jvir.2013.04.023_bib86","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1016\/j.jvir.2010.04.007","article-title":"Microwave tumor ablation: mechanism of action, clinical results, and devices","volume":"21","author":"Lubner","year":"2010","journal-title":"J Vasc Interv Radiol"},{"issue":"suppl","key":"10.1016\/j.jvir.2013.04.023_bib87","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1016\/j.jvir.2009.12.403","article-title":"Cryoablation: mechanism of action and devices","volume":"21","author":"Erinjeri","year":"2010","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2013.04.023_bib88","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4103\/0973-1482.77064","article-title":"High intensity focused ultrasound ablation: a new therapeutic option for solid tumors","volume":"6","author":"Orsi","year":"2010","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.jvir.2013.04.023_bib89","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00330-008-1137-0","article-title":"High-intensity focused ultrasound (HIFU): effective and safe therapy for hepatocellular carcinoma adjacent to major hepatic veins","volume":"19","author":"Zhang","year":"2009","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jvir.2013.04.023_bib90","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1471-2407-7-69","article-title":"Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases: a phase II-study and historical comparison with the surgical approach","volume":"7","author":"Hildebrandt","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jvir.2013.04.023_bib91","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00270-010-9841-y","article-title":"Ultrasound-guided radiological placement of central venous port via the subclavian vein: a retrospective analysis of 500 cases at a single institute","volume":"33","author":"Sakamoto","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2013.04.023_bib92","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1148\/radiol.11081489","article-title":"Transcatheter intraarterial therapies: rationale and overview","volume":"259","author":"Lewandowski","year":"2011","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2013.04.023_bib93","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","article-title":"Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study","volume":"33","author":"Lammer","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2013.04.023_bib94","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.ijrobp.2004.09.004","article-title":"Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers","volume":"60","author":"Kennedy","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jvir.2013.04.023_bib95","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Emami","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jvir.2013.04.023_bib96","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ijrobp.2009.10.062","article-title":"Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization","volume":"79","author":"Riaz","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jvir.2013.04.023_bib97","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/01.RVI.0000159543.28222.73","article-title":"Portal vein embolization in preparation for major hepatic resection: evolution of a new standard of care","volume":"16","author":"Madoff","year":"2005","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2013.04.023_bib98","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1245\/s10434-009-0454-0","article-title":"Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization","volume":"16","author":"Gaba","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib99","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jvir.2013.04.023_bib100","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1038\/ajg.2009.191","article-title":"Management and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program","volume":"104","author":"Garcia-Tsao","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jvir.2013.04.023_bib101","first-page":"311","article-title":"World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective","volume":"19","author":"Ferenci","year":"2010","journal-title":"J Gastrointest Liver Dis"},{"key":"10.1016\/j.jvir.2013.04.023_bib102","doi-asserted-by":"crossref","unstructured":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908\u2013943","DOI":"10.1016\/j.jhep.2011.12.001"},{"key":"10.1016\/j.jvir.2013.04.023_bib103","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/hep.24199","article-title":"Management of hepatocellular carcinoma: an update","volume":"53","author":"Bruix","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2013.04.023_bib104","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/hep.23485","article-title":"A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma","volume":"51","author":"Cabibbo","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2013.04.023_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjsurg.2012.06.010","article-title":"Is less than 5mm as the narrowest surgical margin width in central resections of hepatocellular carcinoma justified?","author":"Jeng","year":"2013","journal-title":"Am J Surg"},{"key":"10.1016\/j.jvir.2013.04.023_bib106","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.surg.2011.12.002","article-title":"Prognostic impact of marginal resection for patients with solitary hepatocellular carcinoma: evidence from 570 hepatectomies","volume":"151","author":"Nara","year":"2012","journal-title":"Surgery"},{"key":"10.1016\/j.jvir.2013.04.023_bib107","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.sla.0000231758.07868.71","article-title":"Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial","volume":"245","author":"Shi","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.jvir.2013.04.023_bib108","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2013.04.023_bib109","unstructured":"Health Resources and Services Administration (HRSA)\/Organ Procurement and Transplantation Network (OPTN) Policies: Policy 3.6 Organ Distribution: Allocation of Livers. Available at: http:\/\/optn.transplant.hrsa.gov\/PoliciesandBylaws2\/policies\/pdfs\/policy_8.pdf. Accessed November 2012"},{"key":"10.1016\/j.jvir.2013.04.023_bib110","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2013.04.023_bib111","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/hep.21933","article-title":"Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?","volume":"47","author":"Livraghi","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2013.04.023_bib112","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/hep.23725","article-title":"Loco-regional treatment of hepatocellular carcinoma","volume":"52","author":"Lencioni","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2013.04.023_bib113","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/hep.26153","article-title":"Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma","volume":"57","author":"Mizukoshi","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2013.04.023_bib114","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00270-009-9736-y","article-title":"Quality improvement guidelines for radiofrequency ablation of liver tumours","volume":"33","author":"Crocetti","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2013.04.023_bib115","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1148\/radiol.2343040153","article-title":"Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver","volume":"234","author":"Lu","year":"2005","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2013.04.023_bib116","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/cncr.11168","article-title":"Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation","volume":"97","author":"Komorizono","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jvir.2013.04.023_bib117","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/hep.510300629","article-title":"Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation","volume":"30","author":"Llovet","year":"1999","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2013.04.023_bib118","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1477-2574.2012.00446.x","article-title":"Systematic review of actual 10-year survival following resection for hepatocellular carcinoma","volume":"14","author":"Gluer","year":"2012","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jvir.2013.04.023_bib119","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1136\/gut.50.1.123","article-title":"Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation","volume":"50","author":"Llovet","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.jvir.2013.04.023_bib120","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1053\/jhep.2002.33156","article-title":"Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma","volume":"35","author":"Lo","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2013.04.023_bib121","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jvir.2013.04.023_bib122","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hep.21980","article-title":"Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis","volume":"47","author":"Kulik","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2013.04.023_bib123","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2009.09.006","article-title":"Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes","volume":"138","author":"Salem","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jvir.2013.04.023_bib124","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1002\/hep.23944","article-title":"Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival","volume":"52","author":"Hilgard","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jvir.2013.04.023_bib125","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1053\/j.gastro.2010.10.049","article-title":"Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma","volume":"140","author":"Salem","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jvir.2013.04.023_bib126","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00000658-199207000-00008","article-title":"Prognostic value of CA 19.9 levels in colorectal cancer","volume":"216","author":"Filella","year":"1992","journal-title":"Ann Surg"},{"key":"10.1016\/j.jvir.2013.04.023_bib127","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3322\/canjclin.51.1.38","article-title":"American Cancer Society guidelines for the early detection of cancer: update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: update 2001\u2014testing for early lung cancer detection","volume":"51","author":"Smith","year":"2001","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jvir.2013.04.023_bib128","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1056\/NEJM199107043250107","article-title":"Screening for colorectal cancer","volume":"325","author":"Ransohoff","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2013.04.023_bib129","doi-asserted-by":"crossref","unstructured":"A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2004; 350:2050\u20132059","DOI":"10.1056\/NEJMoa032651"},{"key":"10.1016\/j.jvir.2013.04.023_bib130","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1200\/JCO.2004.05.063","article-title":"American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer","volume":"22","author":"Benson","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib131","doi-asserted-by":"crossref","first-page":"778","DOI":"10.6004\/jnccn.2009.0056","article-title":"NCCN Clinical Practice Guidelines in Oncology: colon cancer","volume":"7","author":"Engstrom","year":"2009","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.jvir.2013.04.023_bib132","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2001.19.1.157","article-title":"Impact of number of nodes retrieved on outcome in patients with rectal cancer","volume":"19","author":"Tepper","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib133","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"Andre","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib134","unstructured":"National Cancer Institute. Colon Cancer (PDQ). Available at: http:\/\/www.cancer.gov\/cancertopics\/pdq\/treatment\/colon\/HealthProfessional\/page9. Accessed November 2012"},{"key":"10.1016\/j.jvir.2013.04.023_bib135","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2005.00.349","article-title":"Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma","volume":"23","author":"Leonard","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib136","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jvir.2008.01.016","article-title":"Five-year survival following radiofrequency ablation of small, solitary, hepatic colorectal metastases","volume":"19","author":"Gillams","year":"2008","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.jvir.2013.04.023_bib137","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1093\/annonc\/mds053","article-title":"Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004)","volume":"23","author":"Ruers","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib138","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1200\/JCO.2006.09.8467","volume":"25","author":"Diaz-Rubio","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib139","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1056\/NEJMoa0808268","article-title":"Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer","volume":"360","author":"Tol","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2013.04.023_bib140","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1023\/A:1013569329846","article-title":"Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer","volume":"12","author":"Gray","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib141","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/jso.20141","article-title":"Randomised phase 2 trial of SIR-Spheres plus fluorouracil\/leucovorin chemotherapy versus fluorouracil\/leucovorin chemotherapy alone in advanced colorectal cancer","volume":"88","author":"Van Hazel","year":"2004","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib142","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1200\/JCO.2010.28.5643","article-title":"Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy","volume":"28","author":"Hendlisz","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib143","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1007\/s00270-011-0234-7","article-title":"Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases","volume":"35","author":"Seidensticker","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2013.04.023_bib144","first-page":"1387","article-title":"Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study","volume":"32","author":"Fiorentini","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jvir.2013.04.023_bib145","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1200\/JCO.1989.7.11.1646","article-title":"A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial","volume":"7","author":"Hohn","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib146","doi-asserted-by":"crossref","first-page":"459","DOI":"10.7326\/0003-4819-107-4-459","article-title":"Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial","volume":"107","author":"Kemeny","year":"1987","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jvir.2013.04.023_bib147","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/00000658-198712000-00001","article-title":"A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases","volume":"206","author":"Chang","year":"1987","journal-title":"Ann Surg"},{"key":"10.1016\/j.jvir.2013.04.023_bib148","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0140-6736(03)12388-4","article-title":"Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial","volume":"361","author":"Kerr","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jvir.2013.04.023_bib149","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1200\/JCO.2000.18.2.243","volume":"18","author":"Lorenz","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib150","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2005.03.8166","article-title":"Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481)","volume":"24","author":"Kemeny","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib151","doi-asserted-by":"crossref","first-page":"724","DOI":"10.6004\/jnccn.2012.0075","article-title":"Neuroendocrine tumors","volume":"10","author":"Kulke","year":"2012","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jvir.2013.04.023_bib152","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1245\/s10434-007-9566-6","article-title":"Population-based study of islet cell carcinoma","volume":"14","author":"Yao","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib153","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1093\/annonc\/mdn351","article-title":"Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival","volume":"19","author":"Halfdanarson","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib154","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.2011.35.1817","article-title":"Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors","volume":"29","author":"Strosberg","year":"2011","journal-title":"J Clin Oncol"},{"issue":"suppl 7","key":"10.1016\/j.jvir.2013.04.023_bib155","article-title":"Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Oberg","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib156","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1245\/s10434-010-1154-5","article-title":"Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis","volume":"17","author":"Mayo","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib157","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","article-title":"Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system","volume":"15","author":"Oberg","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib158","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00130404-200307000-00008","article-title":"Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience","volume":"9","author":"Gupta","year":"2003","journal-title":"Cancer J"},{"key":"10.1016\/j.jvir.2013.04.023_bib159","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/SLA.0b013e3181728a45","article-title":"90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience","volume":"247","author":"Rhee","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.jvir.2013.04.023_bib160","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/cncr.23685","article-title":"Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases","volume":"113","author":"King","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jvir.2013.04.023_bib161","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/MEG.0b013e328224b935","article-title":"Risk factors for cholangiocarcinoma","volume":"19","author":"Ben-Menachem","year":"2007","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jvir.2013.04.023_bib162","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/SLA.0b013e318176c4d3","article-title":"Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection","volume":"248","author":"Endo","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.jvir.2013.04.023_bib163","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1245\/s10434-008-0180-z","article-title":"A proposed staging system for intrahepatic cholangiocarcinoma","volume":"16","author":"Nathan","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib164","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jamcollsurg.2008.10.017","article-title":"Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients","volume":"208","author":"Lang","year":"2009","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jvir.2013.04.023_bib165","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2013.04.023_bib166","doi-asserted-by":"crossref","first-page":"W205","DOI":"10.2214\/AJR.10.4937","article-title":"Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma","volume":"196","author":"Kim","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jvir.2013.04.023_bib167","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00270-010-9849-3","article-title":"Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience","volume":"33","author":"Carrafiello","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.jvir.2013.04.023_bib168","doi-asserted-by":"crossref","first-page":"e221","DOI":"10.1016\/j.ejrad.2010.09.019","article-title":"Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection","volume":"80","author":"Kim","year":"2011","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.jvir.2013.04.023_bib169","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1002\/cncr.23818","article-title":"Treatment of unresectable cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study","volume":"113","author":"Ibrahim","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jvir.2013.04.023_bib170","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1245\/s10434-009-0777-x","article-title":"Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option","volume":"17","author":"Saxena","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib171","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/cncr.25625","article-title":"Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, Ethiodol, and polyvinyl alcohol: a 2-center study","volume":"117","author":"Kiefer","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jvir.2013.04.023_bib172","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.2012.46.9270","article-title":"New pathologic classification of lung cancer: relevance for clinical practice and clinical trials","volume":"31","author":"Travis","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib173","unstructured":"American Joint Committee on Cancer. Lung Cancer Staging, 7th Edition. Available at: http:\/\/www.cancerstaging.org\/staging\/posters\/lung8.5x11.pdf. Accessed November 2012"},{"key":"10.1016\/j.jvir.2013.04.023_bib174","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(10)70087-5","article-title":"New driver mutations in non-small-cell lung cancer","volume":"12","author":"Pao","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib175","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf. Accessed November 2012"},{"key":"10.1016\/j.jvir.2013.04.023_bib176","unstructured":"National Cancer Institute. Non-Small Cell Lung Cancer Treatment (PDQ). Available at: http:\/\/www.cancer.gov\/cancertopics\/pdq\/treatment\/non-small-cell-lung\/healthprofessional\/Page7#Section_549. Accessed November 2012"},{"key":"10.1016\/j.jvir.2013.04.023_bib177","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2013.04.023_bib178","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jvir.2013.04.023_bib179","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib180","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib181","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jvir.2013.04.023_bib182","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jamcollsurg.2010.03.020","article-title":"Comparison of survival after sublobar resections and ablative therapies for stage I non-small cell lung cancer","volume":"211","author":"Zemlyak","year":"2010","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jvir.2013.04.023_bib183","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1470-2045(08)70155-4","article-title":"Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study)","volume":"9","author":"Lencioni","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib184","unstructured":"National Cancer Institute. Renal Cell Cancer Treatment PDQ. Available at: http:\/\/www.cancer.gov\/cancertopics\/pdq\/treatment\/renalcell\/HealthProfessional\/. Accessed November 2012"},{"key":"10.1016\/j.jvir.2013.04.023_bib185","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: kidney cancer, version 1.2013. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf. Accessed November 2012"},{"key":"10.1016\/j.jvir.2013.04.023_bib186","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s11604-010-0451-z","article-title":"Midterm results of radiofrequency ablation versus nephrectomy for T1a renal cell carcinoma","volume":"28","author":"Takaki","year":"2010","journal-title":"Jpn J Radiol"},{"key":"10.1016\/j.jvir.2013.04.023_bib187","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.juro.2009.07.004","article-title":"Guideline for management of the clinical T1 renal mass","volume":"182","author":"Campbell","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.jvir.2013.04.023_bib188","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/cncr.23896","article-title":"Cryoablation or radiofrequency ablation of the small renal mass : a meta-analysis","volume":"113","author":"Kunkle","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.jvir.2013.04.023_bib189","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2214\/AJR.12.8618","article-title":"Percutaneous ablation of renal masses measuring 3.0cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation","volume":"200","author":"Atwell","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jvir.2013.04.023_bib190","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2214\/ajr.185.1.01850064","article-title":"Radiofrequency ablation of renal cell carcinoma: part 1, Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors","volume":"185","author":"Gervais","year":"2005","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jvir.2013.04.023_bib191","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2214\/AJR.07.2258","article-title":"Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas","volume":"189","author":"Zagoria","year":"2007","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jvir.2013.04.023_bib192","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2214\/AJR.06.1152","article-title":"Percutaneous cryoablation of large renal masses: technical feasibility and short-term outcome","volume":"188","author":"Atwell","year":"2007","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jvir.2013.04.023_bib193","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2214\/AJR.10.5182","article-title":"Percutaneous cryoablation of renal lesions with radiographic ice ball involvement of the renal sinus: analysis of hemorrhagic and collecting system complications","volume":"196","author":"Rosenberg","year":"2011","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jvir.2013.04.023_bib194","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.urology.2005.11.058","article-title":"Clinical sequelae of radiographic iceball involvement of collecting system during computed tomography-guided percutaneous renal tumor cryoablation","volume":"67","author":"Warlick","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.jvir.2013.04.023_bib195","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1089\/end.2008.0499","article-title":"General anesthesia and contrast-enhanced computed tomography to optimize renal percutaneous radiofrequency ablation: multi-institutional intermediate-term results","volume":"23","author":"Gupta","year":"2009","journal-title":"J Endourol"},{"key":"10.1016\/j.jvir.2013.04.023_bib196","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s003300050675","article-title":"Is there still a place for angiography in the management of renal mass lesions?","volume":"9","author":"Roy","year":"1999","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jvir.2013.04.023_bib197","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"issue":"suppl","key":"10.1016\/j.jvir.2013.04.023_bib198","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.jvir.2013.04.023_bib199","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/1097-0142(19820901)50:5<893::AID-CNCR2820500515>3.0.CO;2-Y","article-title":"The palliation of symptomatic osseous metastases: final results of the Study by the Radiation Therapy Oncology Group","volume":"50","author":"Tong","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.jvir.2013.04.023_bib200","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1148\/radiol.11101384","article-title":"Critical review and state of the art in interventional oncology: benign and metastatic disease involving bone","volume":"262","author":"Rosenthal","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2013.04.023_bib201","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1200\/JCO.2004.03.097","article-title":"Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study","volume":"22","author":"Goetz","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib202","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/cncr.24837","article-title":"Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trial","volume":"116","author":"Dupuy","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.jvir.2013.04.023_bib203","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1148\/radiol.2412051247","article-title":"Painful metastases involving bone: percutaneous image-guided cryoablation\u2014prospective trial interim analysis","volume":"241","author":"Callstrom","year":"2006","journal-title":"Radiology"},{"key":"10.1016\/j.jvir.2013.04.023_bib204","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/SPC.0b013e328349652d","article-title":"Role of vertebral augmentation procedures in the management of vertebral compression fractures in cancer patients","volume":"5","author":"Aghayev","year":"2011","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.jvir.2013.04.023_bib205","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S1470-2045(11)70008-0","article-title":"Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial","volume":"12","author":"Berenson","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jvir.2013.04.023_bib206","first-page":"3129","article-title":"Radiofrequency heat ablation and vertebroplasty in the treatment of neoplastic vertebral body fractures","volume":"24","author":"Masala","year":"2004","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jvir.2013.04.023_bib207","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11547-009-0431-5","article-title":"Combined radiofrequency and kyphoplasty in painful osteolytic metastases to vertebral bodies","volume":"115","author":"Sandri","year":"2010","journal-title":"Radiol Med"},{"key":"10.1016\/j.jvir.2013.04.023_bib208","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3171\/2010.11.SPINE09909","article-title":"Balloon kyphoplasty in the treatment of metastatic tumors of the upper thoracic spine","volume":"14","author":"Eleraky","year":"2011","journal-title":"J Neurosurg Spine"},{"key":"10.1016\/j.jvir.2013.04.023_bib209","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3171\/spi.2007.6.4.5","article-title":"Treatment of painful osteoporotic compression and burst fractures using kyphoplasty: a prospective observational design","volume":"6","author":"Stoffel","year":"2007","journal-title":"J Neurosurg Spine"}],"container-title":["Journal of Vascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044313009470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1051044313009470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T16:22:39Z","timestamp":1563294159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051044313009470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":209,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S1051044313009470"],"URL":"https:\/\/doi.org\/10.1016\/j.jvir.2013.04.023","relation":{},"ISSN":["1051-0443"],"issn-type":[{"value":"1051-0443","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}